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Development of mucosal vaccines for inducing immunity in the female reproductive 
tract would have profound implications for the prevention of sexually transmitted 
diseases. Despite numerous efforts, no such vaccines are currently available for human 
use. The main objective of this doctoral thesis was to develop novel immunization 
approaches to generate immunity in the female genital tract with special emphasis on 
immunity against genital herpes. 
 
Mammalian innate immune systems sense and respond to pathogens through a series of 
pattern recognition receptors such as Toll-like receptors (TLRs). Detection of pathogen 
associated molecular patterns by TLRs triggers a signaling pathway mainly through 
adaptor protein MyD88, which results in a coordinated set of immune responses that 
includes both innate and acquired immunity. By using a well-established mouse model 
of genital HSV-2 infection, it was shown in this thesis that the efficacy of intramuscular 
immunization with a DNA vaccine encoding glycoprotein D (gD) from HSV-2 can be 
improved with a timely administration of synthetic oligodeoxynucleotide (ODN) 
containing immunostimulatory CpG motifs, a TLR9 ligand. Another important finding 
in this thesis work was introduction of CpG ODN as a potent vaginal adjuvant for 
induction of acquired immunity in the female genital tract as well as for systemic 
immune response. Thus, vaginal immunization with HSV-2 gD in combination with 
CpG ODN induced a potent gD specific antibody as well as cellular immunity, and 
conferred protection against subsequent vaginal challenge with a lethal dose of HSV-2.  
 
The potential of rectal immunization route to induce protective immunity in the female 
genital tract was also investigated. Thus, rectal immunization with a live attenuated 
HSV-2 TK- was shown to confer antibody and cellular response as well as protection 
against an otherwise lethal vaginal challenge with a virulent HSV-2 strain. Importantly, 
unlike intravaginal route, rectal route was shown to be independent of sex hormonal 
influence. It was also documented that TLR/MyD88 signaling pathway is important for 
innate immune protection against primary genital herpes. By contrast, the usage of 
MyD88 was shown to be dispensable for induction of acquired immune protection 
induced by vaginal or rectal immunization with HSV-2 TK-. In addition, while rectal 
immunization with the TLR/MyD88 targeting adjuvant CpG ODN in combination with 
gD failed to elicit protective immunity, rectal immunization with cholera toxin and gD 
conferred a potent antibody and cellular immune responses as well as protection against 
genital herpes. These results have implications for the development of vaccines to 
generate immunity in the female genital tract against sexually transmitted infections. 
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